Complete Genomics Announces New Technology Developed to Set Standard for Clinical-Grade Genomes
Complete Genomics, Inc. (Nasdaq: GNOM) today announced that its Long Fragment Read (LFR) technology for whole genome sequencing dramatically improves accuracy, enables fully-phased genomes, and significantly reduces the amount of DNA required for testing. Complete's LFR technology should accelerate the use of whole genome sequencing by physicians to diagnose and treat their patients.
"We expect the introduction of this technological breakthrough to accelerate the move of whole genome sequencing into patient care, which in turn will begin to change the face of medicine," said Dr. Clifford Reid, Complete Genomics' chairman, president and CEO.
"The Nature paper by Peters et al. describes how our LFR technology uses 'barcoded' DNA to generate whole genome sequencing with approximately one error in 10 million base pairs, or just 600 errors in an entire human genome," said Dr. Rade Drmanac, the company's chief scientific officer and inventor of the LFR technology. "This represents a 10-fold increase in accuracy for Complete and is unmatched by any high-sensitivity method currently available."
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.